Credit Suisse’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.82M | Buy |
63,024
+507
| +0.8% | +$14.7K | ﹤0.01% | 1909 |
|
|
2023
Q4 | $1.43M | Buy |
62,517
+12,404
| +25% | +$284K | ﹤0.01% | 2100 |
|
|
2023
Q3 | $836K | Sell |
50,113
-12,721
| -20% | -$212K | ﹤0.01% | 2386 |
|
|
2023
Q2 | $1.74M | Buy |
62,834
+24,833
| +65% | +$686K | ﹤0.01% | 1996 |
|
|
2023
Q1 | $874K | Buy |
38,001
+6,764
| +22% | +$156K | ﹤0.01% | 2395 |
|
|
2022
Q4 | $341K | Sell |
31,237
-795
| -2% | -$8.67K | ﹤0.01% | 2958 |
|
|
2022
Q3 | $270K | Buy |
32,032
+217
| +0.7% | +$1.83K | ﹤0.01% | 3104 |
|
|
2022
Q2 | $251K | Sell |
31,815
-1,083
| -3% | -$8.54K | ﹤0.01% | 3222 |
|
|
2022
Q1 | $779K | Buy |
32,898
+4,550
| +16% | +$108K | ﹤0.01% | 2686 |
|
|
2021
Q4 | $969K | Buy |
28,348
+653
| +2% | +$22.3K | ﹤0.01% | 2605 |
|
|
2021
Q3 | $491K | Buy |
27,695
+240
| +0.9% | +$4.26K | ﹤0.01% | 3000 |
|
|
2021
Q2 | $1.23M | Buy |
27,455
+6,215
| +29% | +$279K | ﹤0.01% | 2497 |
|
|
2021
Q1 | $549K | Sell |
21,240
-29,583
| -58% | -$765K | ﹤0.01% | 2896 |
|
|
2020
Q4 | $1.03M | Buy |
50,823
+23,347
| +85% | +$471K | ﹤0.01% | 2563 |
|
|
2020
Q3 | $537K | Buy |
+27,476
| New | +$537K | ﹤0.01% | 2640 |
|
|
2016
Q4 | – | Sell |
-16,924
| Closed | -$358K | – | 3782 |
|
|
2016
Q3 | $358K | Buy |
+16,924
| New | +$358K | ﹤0.01% | 3255 |
|